Annual Accounts Receivable
$3.43 M
-$32.55 M-90.46%
December 31, 2023
Summary
- As of February 21, 2025, CTMX annual accounts receivable is $3.43 million, with the most recent change of -$32.55 million (-90.46%) on December 31, 2023.
- During the last 3 years, CTMX annual accounts receivable has risen by +$2.63 million (+330.08%).
- CTMX annual accounts receivable is now -90.46% below its all-time high of $35.99 million, reached on December 31, 2022.
Performance
CTMX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$3.35 M
+$577.00 K+20.79%
September 30, 2024
Summary
- As of February 21, 2025, CTMX quarterly accounts receivable is $3.35 million, with the most recent change of +$577.00 thousand (+20.79%) on September 30, 2024.
- Over the past year, CTMX quarterly accounts receivable has increased by +$933.00 thousand (+38.57%).
- CTMX quarterly accounts receivable is now -97.42% below its all-time high of $130.01 million, reached on March 31, 2020.
Performance
CTMX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CTMX Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -90.5% | +38.6% |
| 3 y3 years | +330.1% | +38.6% |
| 5 y5 years | +3438.1% | +38.6% |
CTMX Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -90.5% | +334.4% | -90.7% | +324.3% |
| 5 y | 5-year | -90.5% | >+9999.0% | -97.4% | >+9999.0% |
| alltime | all time | -90.5% | >+9999.0% | -97.4% | >+9999.0% |
CytomX Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $3.35 M(+20.8%) |
| Jun 2024 | - | $2.77 M(-78.9%) |
| Mar 2024 | - | $13.18 M(+283.9%) |
| Dec 2023 | $3.43 M(-90.5%) | $3.43 M(+41.9%) |
| Sep 2023 | - | $2.42 M(+27.1%) |
| Jun 2023 | - | $1.90 M(+74.6%) |
| Mar 2023 | - | $1.09 M(-97.0%) |
| Dec 2022 | $35.99 M(+4455.2%) | $35.99 M(+2002.0%) |
| Sep 2022 | - | $1.71 M(+68.8%) |
| Jun 2022 | - | $1.01 M(-0.2%) |
| Mar 2022 | - | $1.02 M(+28.6%) |
| Dec 2021 | $790.00 K(-1.0%) | $790.00 K(-10.9%) |
| Sep 2021 | - | $887.00 K(-4.7%) |
| Jun 2021 | - | $931.00 K(+23.1%) |
| Mar 2021 | - | $756.00 K(-5.3%) |
| Dec 2020 | $798.00 K(+6038.5%) | $798.00 K(+47.0%) |
| Sep 2020 | - | $543.00 K(+163.6%) |
| Jun 2020 | - | $206.00 K(-99.8%) |
| Mar 2020 | - | $130.01 M(>+9900.0%) |
| Dec 2019 | $13.00 K | $13.00 K(+85.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $7000.00(-99.9%) |
| Jun 2019 | - | $10.00 M(>+9900.0%) |
| Mar 2019 | - | $44.00 K(-54.6%) |
| Dec 2018 | $97.00 K(-99.0%) | $97.00 K(+73.2%) |
| Sep 2018 | - | $56.00 K(-99.8%) |
| Jun 2018 | - | $25.14 M(>+9900.0%) |
| Mar 2018 | - | $81.00 K(-99.2%) |
| Dec 2017 | $10.14 M(+369.6%) | $10.14 M(-74.8%) |
| Sep 2017 | - | $40.18 M(>+9900.0%) |
| Jun 2017 | - | $158.00 K(-25.8%) |
| Mar 2017 | - | $213.00 K(-90.1%) |
| Dec 2016 | $2.16 M(+480.4%) | $2.16 M(+799.6%) |
| Sep 2016 | - | $240.00 K(-15.8%) |
| Jun 2016 | - | $285.00 K(-9.8%) |
| Mar 2016 | - | $316.00 K(-15.1%) |
| Dec 2015 | $372.00 K(-80.2%) | $372.00 K(-8.4%) |
| Sep 2015 | - | $406.00 K(-35.7%) |
| Jun 2015 | - | $631.00 K(-66.3%) |
| Dec 2014 | $1.88 M(+691.1%) | $1.88 M |
| Dec 2013 | $237.00 K | - |
FAQ
- What is CytomX Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for CytomX Therapeutics?
- What is CytomX Therapeutics annual accounts receivable year-on-year change?
- What is CytomX Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for CytomX Therapeutics?
- What is CytomX Therapeutics quarterly accounts receivable year-on-year change?
What is CytomX Therapeutics annual accounts receivable?
The current annual accounts receivable of CTMX is $3.43 M
What is the all time high annual accounts receivable for CytomX Therapeutics?
CytomX Therapeutics all-time high annual accounts receivable is $35.99 M
What is CytomX Therapeutics annual accounts receivable year-on-year change?
Over the past year, CTMX annual accounts receivable has changed by -$32.55 M (-90.46%)
What is CytomX Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of CTMX is $3.35 M
What is the all time high quarterly accounts receivable for CytomX Therapeutics?
CytomX Therapeutics all-time high quarterly accounts receivable is $130.01 M
What is CytomX Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, CTMX quarterly accounts receivable has changed by +$933.00 K (+38.57%)